The UK government has announced a 600 million pounds ($ 764 million) financing container to create a new service for health data research, which reduces the red strip for researchers.
The service has been developed in cooperation with the Wellcome Trust, the service will create a single safe access point to national data groups. The money will also support the rapid tracking of clinical trials to accelerate the development of new treatments.
The government hopes to reduce funding from the time of preparation to 150 days by March 2026-The latest data collected in 2022 found that the preparation time exceeds 250 days. The government said that this will be achieved by “cutting the bureaucracy and uniting contracts” to avoid the time it spends in negotiations.
In May 2023, Lord James Oshunisi published a review of the UK clinical trial sector, which found that the country had moved from fourth to tenth as a global shareholder in clinical trials. The review highlighted 27 main recommendations to improve the country’s position on the world stage.
Investing in clinical trials, five months after the UK government has established a new regulatory framework for clinical experiences in Parliament to improve the efficiency of experiences. Comprehensive reform has been removed refined requirements and included in the law the shared review and notification plan for some applications and initial amendments to the clinical experience.
Varma CEOs of Change welcome
This announcement follows a request from the Gharma giant GSK, who asked the UK government to provide more comprehensive access to national health records to support the development of medicines, according to a report he submitted Bloomberg.
In response to the announcement of the April 7 government, the CEO of GSK, Emma and Al -Mili said: “We welcome the ambition and urgency today about health data and clinical experiences. The UK has unique potential to collect health data safely with the NHS system that is now studying, and recognizes the implementation of what increases the value of discrimination and economy. To support.”
“It has the ability to be a changing games, by accelerating safe, trustworthy research, which depends on data to improve researchers in the field of patient health- to develop and test new methods to prevent, diagnose and treat health conditions such as cancer, dementia, heart disease, depression and inflammation Joints and infectious outbreaks.
UK investment can make a “global pioneer in clinical research”, according to Ganet Valentine, CEO of Innovation and Research Policy, the British Pharmaceutical Industry Association (ABPI).
Valentin said: “The scope and ambition of the Prime Minister’s announcement explains today that he understands the huge opportunity for the United Kingdom to be a global leader in clinical research, and that opening access to health data and the speed of preparing clinical experiences is essential to achieving this goal,” Valentin said.
Other calls make the UK government
Last week at the annual ABPI 2025 conference, the industry called on the UK government to “solve the volunteer plan for the branded drug price crisis.” At the same conference, the Wes Streeting Minister pledged “quick work to thwart VPAG”, adding that his plan belonging to drugs selling drugs, gentle regulations, and canceling NHS England.
